Abstract:Yule Wang, &ast Bei Li, &ast Yingjuan Zhang, &ast Ruiling Lu, Qianzhuo Wang, Yue Gao Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Department of Geriatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yue Gao, Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Department of Geriatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, 261 huansha Road, Shangcheng District, Hangzhou, 310006, People's Republic of China, Email Background: Acute lung injury (ALI) is a life-threatening clinical syndrome with high mortality. Currently, the safe and effective therapies for ALI patients are still limited. Qingfei Huoxue decoction (QFHXD) is a hospital agreement prescription for treating pulmonary diseases and displays a remarkable efficacy. However, the pharmacological effect of QFHXD on preventing lipopolysaccharide (LPS)-induced ALI has yet to be reported, let alone questions of potential molecular mechanisms and anti-ALI active substances. Methods: To answer the above-mentioned questions, histopathological observation and kit detection were performed to estimate the protective effect of QFHXD pretreatment against LPS-induced ALI. Based on comprehensive chemical profiling of QFHXD, a network pharmacology strategy and experimental validation were integrated to elucidate the underlying functional mechanisms. The potential anti-ALI active components were identified by molecular docking. The anti-ALI activity of narirutin and its anti-inflammatory mechanism were further validated using animal and molecular experiments. Results: Pretreatment with different doses of QFHXD effectively mitigated histopathological lesions and systemic inflammation caused by LPS stimulation. A detailed analysis of established compound-target-disease network revealed the strong correlation between anti-ALI action of QFHXD and inflammatory mechanisms. Compared with the model group, QFHXD intervention markedly restrained the abnormally increased transcription and protein levels of pro-inflammatory factors (TLR4, NF-κB, IL-6, IL-1β, and TNF-α) in lung tissues of ALI mice. The results of molecular docking highlighted the anti-ALI potential of narirutin targeting to TLR4 and NF-κB p65. In addition to the protective effect of narirutin on suppressing LPS-induced pathological changes, we found that narirutin pretreatment effectively normalized the disordered protein levels of above pro-inflammatory factors of ALI mice. Conclusion: These interesting findings indicate the beneficial effects of QFHXD and its active component narirutin against ALI partly via regulating TLR4/NF-κB mediated inflammation. This work contributes to the development of novel medications for ALI patients. Keywords: Qingfei Huoxue decoction, narirutin, LPS-induced acute lung injury, network pharmacology, TLR4/NF-κB pathway, inflammatory response Graphical Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are the leading causes of acute respiratory failure in critically ill patients with high morbidity and poor clinical outcomes. 1 Especially, with the outbreak of the Coronavirus Disease 2019 (COVID-19), ALI/ARDS significantly contributes to the mortality in patients with COVID‐19. 2 As a major clinical problem worldwide, a variety of pulmonary and extra-pulmonary triggers accelerate the onset of ALI, such as pneumonia, pulmonary contusion, non-pulmonary sepsis, severe trauma with shock, and transfusion-related ALI. 3 The pathological characteristics of ALI are mainly manifested by diffuse alveolar damage with dysfunction of alveolar epithelial-capillary endothelial barrier, pulmonary edema, local inflammatory accumulation (activation of immune cells and production of pro-inflammatory mediators), eventually resulting in severe lung consolidation. 1,4 To date, apart from the recommended non-pharmacological intervention (lung-protective mechanical ventilation), corticosteroids, phosphodiesterase inhibitors, and neuromuscular blockers appear to be the most promising medications. 5,6 However, the limited options and medical burden urgently call for the novel therapeutic approaches. In China, Chinese medicines (CMs) have a long history in the clinical practice of ALI. 7 From the perspective of traditional Chinese medicine (TCM), the main pathogenesis of ALI can be summarized as heat, toxin, phlegm, and stasis -Abstract Truncated-

Qingfei Huoxue Decoction and Its Active Component Narirutin Alleviate LPS-Induced Acute Lung Injury by Regulating TLR4/NF-κB Pathway Mediated Inflammation

Network Pharmacology and Experimental Validation of the Anti-Inflammatory Effect of Tingli Dazao Xiefei Decoction in Acute Lung Injury Treatment

Qingfei Litan Decoction Against Acute Lung Injury/Acute Respiratory Distress Syndrome: The Potential Roles of Anti-Inflammatory and Anti-Oxidative Effects

Qinhuo Shanggan oral solution resolves acute lung injury by down-regulating TLR4/NF-κB signaling cascade and inhibiting NLRP3 inflammasome activation

Huoxiang Zhengqi Oral Liquid Attenuates LPS-Induced Acute Lung Injury by Modulating Short-Chain Fatty Acid Levels and TLR4/NF- κ B p65 Pathway

Qingwenzhike Prescription Alleviates Acute Lung Injury Induced by LPS via Inhibiting TLR4/NF-kB Pathway and NLRP3 Inflammasome Activation

Huoxiang Zhengqi Oral Liquid Attenuates LPS-Induced Acute Lung Injury by Modulating Short-Chain Fatty Acid Levels and TLR4/NF-κB p65 Pathway

Exploring the mechanisms of Huangqin Qingfei Decoction on acute lung injury by LC-MS combined network pharmacology analysis

Guben Qingfei decoction attenuates LPS-induced acute lung injury by modulating the TLR4/NF-κB and Keap1/Nrf2 signaling pathways

Inhibition of inflammasome activation via sphingolipid pathway in acute lung injury by Huanglian Jiedu decoction: An integrative pharmacology approach

Nuciferine Ameliorates Inflammatory Responses by Inhibiting the TLR4-Mediated Pathway in Lipopolysaccharide-Induced Acute Lung Injury

The protective effects of Mai-Luo-Ning injection against LPS-induced acute lung injury via the TLR4/NF-κB signalling pathway

Lianhua Qingke ameliorates lipopolysaccharide-induced lung injury by inhibiting neutrophil extracellular traps formation and pyroptosis

Network Pharmacology and Molecular Docking to Explore Polygoni Cuspidati Rhizoma Et Radix Treatment for Acute Lung Injury.

Lianqinjiedu decoction attenuates LPS-induced inflammation and acute lung injury in rats via TLR4/NF-κB pathway

Dddt_a_215712 4161..4171

Jinyinqingre Oral Liquid alleviates LPS-induced acute lung injury by inhibiting the NF-κB/NLRP3/GSDMD pathway

Exploring the bioactive substances and mechanisms of Ligusticum chuanxiong Hort. treating acute lung injury based on combined network pharmacological, phytochemical, and pharmacological investigations

Polygala tenuifolia Willd. extract alleviates LPS-induced acute lung injury in rats via TLR4/NF-κB pathway and NLRP3 inflammasome suppression

The phytochemical constituents and protective effect of Fritillaria hupehensis on acute lung injury

Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome